Griffin Securities, Inc. Announces Investment Opinion on ZIOPHARM Oncology, Inc.

NEW YORK--(BUSINESS WIRE)--Griffin Securities, Inc. Updates Research Coverage on ZIOPHARM Oncology, Inc. (NasdaqCM:ZIOP) with a BUY Rating and establishes a 12-month target of $15 per share. Chrystyna Bedrij, Director of Research issued the report.

Griffin Securities, Inc. specializes in identifying small cap emerging growth investment opportunities. The firm is a member of the Financial Industry Regulatory Authority (FINRA Broker ID 43229) and the Securities Investor Protection Corporation.

For a copy of the report, including disclosures, contact:

Griffin Securities, Inc.

Chrystyna Bedrij, 212-509-9500